BR112018001116A2 - inibidor de fosfodiesterase 4 (pde4) para o tratamento de nefropatia diabética - Google Patents
inibidor de fosfodiesterase 4 (pde4) para o tratamento de nefropatia diabéticaInfo
- Publication number
- BR112018001116A2 BR112018001116A2 BR112018001116-9A BR112018001116A BR112018001116A2 BR 112018001116 A2 BR112018001116 A2 BR 112018001116A2 BR 112018001116 A BR112018001116 A BR 112018001116A BR 112018001116 A2 BR112018001116 A2 BR 112018001116A2
- Authority
- BR
- Brazil
- Prior art keywords
- inhibitor
- phosphodiesterase
- treatment
- diabetic nephropathy
- pde4
- Prior art date
Links
- 208000007342 Diabetic Nephropathies Diseases 0.000 title abstract 2
- 208000033679 diabetic kidney disease Diseases 0.000 title abstract 2
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 title 1
- 101100296719 Caenorhabditis elegans pde-4 gene Proteins 0.000 title 1
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 title 1
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 abstract 3
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 abstract 3
- 102000015427 Angiotensins Human genes 0.000 abstract 1
- 108010064733 Angiotensins Proteins 0.000 abstract 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 abstract 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 abstract 1
- 239000002532 enzyme inhibitor Substances 0.000 abstract 1
- 229940125532 enzyme inhibitor Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562198213P | 2015-07-29 | 2015-07-29 | |
| US62/198,213 | 2015-07-29 | ||
| PCT/EP2016/067968 WO2017017165A1 (en) | 2015-07-29 | 2016-07-28 | Pde4 inhibitor for the treatment of diabetic nephropathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018001116A2 true BR112018001116A2 (pt) | 2018-09-11 |
Family
ID=56551407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018001116-9A BR112018001116A2 (pt) | 2015-07-29 | 2016-07-28 | inibidor de fosfodiesterase 4 (pde4) para o tratamento de nefropatia diabética |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20200179369A1 (enExample) |
| EP (1) | EP3328381A1 (enExample) |
| JP (1) | JP2018521077A (enExample) |
| CN (1) | CN108135886A (enExample) |
| BR (1) | BR112018001116A2 (enExample) |
| CA (1) | CA2992796A1 (enExample) |
| EA (1) | EA201890346A1 (enExample) |
| MA (1) | MA42519A (enExample) |
| WO (1) | WO2017017165A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11179384B2 (en) * | 2016-08-26 | 2021-11-23 | Takeda Gmbh | Treatment of nonalcoholic fatty liver disease |
| CN107157999A (zh) * | 2017-05-27 | 2017-09-15 | 青岛海蓝医药有限公司 | 川芎嗪硝酮衍生物在预防和治疗糖尿病并发症疾病中的应用 |
| CN114053281B (zh) * | 2020-08-10 | 2025-05-27 | 成都文鼎科技发展有限公司 | 治疗慢性肾病的方法和药物组合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7413751B2 (en) * | 2001-10-25 | 2008-08-19 | Depomed, Inc. | Methods of treatment using a gastric retained losartan dosage |
| US7157584B2 (en) * | 2004-02-25 | 2007-01-02 | Takeda Pharmaceutical Company Limited | Benzimidazole derivative and use thereof |
| CN104803974A (zh) * | 2004-03-03 | 2015-07-29 | 塔科达有限责任公司 | 新的羟基-6-杂芳基菲啶及其作为pde4抑制剂的用途 |
| GB0504103D0 (en) * | 2005-02-28 | 2005-04-06 | Syngenta Ltd | Novel method |
-
2016
- 2016-07-28 MA MA042519A patent/MA42519A/fr unknown
- 2016-07-28 CN CN201680056550.2A patent/CN108135886A/zh active Pending
- 2016-07-28 EP EP16744758.0A patent/EP3328381A1/en not_active Withdrawn
- 2016-07-28 WO PCT/EP2016/067968 patent/WO2017017165A1/en not_active Ceased
- 2016-07-28 BR BR112018001116-9A patent/BR112018001116A2/pt not_active Application Discontinuation
- 2016-07-28 CA CA2992796A patent/CA2992796A1/en not_active Abandoned
- 2016-07-28 US US15/746,560 patent/US20200179369A1/en not_active Abandoned
- 2016-07-28 JP JP2018503204A patent/JP2018521077A/ja active Pending
- 2016-07-28 EA EA201890346A patent/EA201890346A1/ru unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2992796A1 (en) | 2017-02-02 |
| CN108135886A (zh) | 2018-06-08 |
| WO2017017165A1 (en) | 2017-02-02 |
| US20200179369A1 (en) | 2020-06-11 |
| EP3328381A1 (en) | 2018-06-06 |
| JP2018521077A (ja) | 2018-08-02 |
| MA42519A (fr) | 2018-06-06 |
| EA201890346A1 (ru) | 2018-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017003142A1 (es) | Composiciones que comprenden cepas bacterianas | |
| PH12017500509A1 (en) | Benzyl substituted indazoles as bub1 inhibitors | |
| MX379270B (es) | Composiciones que comprenden cepas bacterianas. | |
| BR112018011709A2 (pt) | inibidores bicíclicos de pad4 | |
| BR112018004620A2 (pt) | moduladores da expressão de kras | |
| PE20180266A1 (es) | Composiciones que comprenden cepas bacterianas | |
| BR112016026950A2 (pt) | composições de rnai para angiotensinogênio (agt) e métodos de uso das mesmas | |
| HK1255452A1 (zh) | 改进的爱帕琳肽受体(apj)激动剂及其用途 | |
| EA201790998A1 (ru) | Иммуннорегуляторные агенты | |
| EA201490922A1 (ru) | ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ | |
| ECSP13012394A (es) | Nuevas formas de dosificación de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa | |
| MX389449B (es) | Composiciones de inh-c1 y métodos para la prevención y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa. | |
| BR112017000024A2 (pt) | composição para tratamento de tecidos que compreende uma nanoemulsão polimérica de aminossiloxano | |
| MA40998A (fr) | Thérapies contre une envenimation, ainsi que compositions, systèmes et kits pharmaceutiques associés | |
| EP4361178A3 (en) | Acid-alpha glucosidase variants and uses thereof | |
| MX2018006700A (es) | Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4). | |
| MX2018004674A (es) | Moduladores de interacción de sestrina-gator2 y sus usos. | |
| BR112017002060A2 (pt) | novo uso | |
| EA201792604A1 (ru) | Ингибиторы аутотаксина и их применения | |
| ECSP19077969A (es) | Compuesto heterociclico | |
| MX2017004808A (es) | Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple. | |
| IL250026A0 (en) | Novel 5,2-disubstituted pyrimidines as pde4 inhibitors | |
| MX2017005249A (es) | Compuestos para usarse en el tratamiento antihelmintico. | |
| TW201613892A (en) | Forms and compositions of an ERK inhibitor | |
| CL2015002113A1 (es) | Compuestos de azetidinloxifenilpirrolidina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |